Stoke (STOK): Operating Sales Margin

Stoke Therapeutics (STOK) - corporate logo

Stoke Therapeutics (STOK) demonstrates high macro-resilience due to its liquidity reserve and independence from economic cycles. The business relies on the development of RNA-based drugs to combat the root causes of rare pathologies, focusing on insurance payouts. Demand within the genetic disease niche remains critical with a complete absence of saturation. An assessment of operating profitability helps filter out the noise, and -913.10 describes the current status of the metric.

STOK - stoketherapeutics.com Operating Profit Ratio over the range 07/04/2022 - 11/19/2026

Analytical breakdowns for Stoke Therapeutics

- share price and consensus valuation forecast:
Initial company analysis:STOK, Stoke Corp
Finished products of Stoke Therapeutics

Operating margin reflects the efficiency of profit generation from core business operations before accounting for financial expenses and taxes. This ratio measures the share of operating income in revenue, determining the internal profitability of the business model. Analyzing the trajectory of operating profitability allows for the identification of cost management dynamics between reporting periods. For Stoke Therapeutics (STOK), this indicator demonstrates the cost of developing breakthrough RNA technologies. The efficiency of molecular therapy directly impacts the future capitalization of the asset.

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability